Baird served as joint-bookrunner on this transaction.
AboutExact Sciences Corporation (“Exact” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 7,000,000 shares of common stock at a price of $25.50 per share, generating gross proceeds of $178.5 million. The Company intends to use the net proceeds from the offering to fund expansion of the Company’s Cologuard commercialization activities, to fund its product development efforts, and for general corporate and working capital purposes.
Exact is a molecular diagnostics company currently focused on the early detection and prevention of some of the deadliest forms of cancer. Exact has developed Cologuard™, an accurate, non-invasive, patient-friendly screening test for the early detection of colorectal cancer and pre-cancer, and is currently working on the development of tests for lung cancer, pancreatic cancer and esophageal cancer. The Company is headquartered in Madison, Wisconsin.
For additional information about this transaction, please contact:
- July 2015
- Exact Sciences Corporation
- Target Location
- North America